Paradigm Health Co-Founder and Chief Strategy Officer Jonathan Hirsch will join senior Japanese health officials and industry leaders to present on how the company is collaborating to build a more efficient Japanese clinical research ecosystem, establishing Japan as a global destination for clinical development.
WHAT:
At BioJapan 2026, Paradigm Health Co-Founder and Chief Strategy Officer Jonathan Hirsch will present during the session titled “From Clinical Trials to Investment Returns: Toward the Rebuilding of the Bioecosystem in Japan.”
Speakers will present on the steps that hospitals, regulators, and technology companies are taking to create efficiencies in Japan’s clinical development environment to eliminate drug loss and attract more biopharmaceutical sponsors to run more trials in Japan.
Paradigm Health is honored to present alongside Dr. Toshihiko Doi of National Cancer Center East and Dr. Yasuhiro Fujiwara of the PMDA. Hirsch will present on the current and future use of Paradigm Health’s AI-native platform in Japan to help create efficiency in study data collection and monitoring, leveraging lessons learned in the United States, including from experience with the U.S. FDA on Real-Time Clinical Trials.
WHO:
- Jonathan Hirsch, Co-Founder and Chief Strategy Officer, Paradigm Health
- Dr. Toshihiko Doi, Director, National Cancer Center Hospital East
- Dr. Yasuhiro Fujiwara, Chief Executive, Pharmaceuticals and Medical Devices Agency
- Takuji Achiwa, Chief Development Officer, A-SEEDS Co., Ltd.
Moderator:
Daisuke Yoshizumi, Managing Director, JPMorgan Securities Japan
WHEN:
Wednesday, October 7, 2026
15:30-17:00 Japan Standard Time
WHERE:
PACIFICO Yokohama
G303 - G304
Yokohama, Japan
WHY IT MATTERS:
“Drug loss,” when medicines available elsewhere are delayed or never introduced in Japan, can limit patients’ access to innovative treatments. By making clinical trials faster and easier to conduct across a broader range of hospitals, Japan can attract more global studies, strengthen its role in drug development, and help ensure that promising new therapies reach Japanese patients. The panel will explore the infrastructure, partnerships, and data-enabled approaches that can help Japan bring more global trials to a wider range of Japanese hospitals and patients.
MEDIA AVAILABILITY:
Hirsch is available during and after BioJapan for interviews addressing:
- How Japan can attract more international studies
- What hospitals need to incorporate research more readily into clinical care
- Lessons Japan can consider from emerging data-enabled research models worldwide
- Paradigm Health’s work with Japanese institutions to modernize clinical research infrastructure
EVENT AND SESSION DETAILS:
BioJapan 2026
Media Contact: Lisa Johnson, lisa.johnson@paradigmhealth.ai
